TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy

BACKGROUND AND PURPOSE: Cisplatin–paclitaxel (TP) combination chemotherapy as the first-line therapy for numerous cancers is hindered by its inadequate accumulation in tumors and severe side effects resulting from non-specific distribution. The aim of this study is to explore whether TMTP1-modified,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Guiying, Wang, Xueqian, Zhou, Ying, Zou, Chenming, Wang, Ling, Wang, Wei, Zhang, Danya, Xu, Hanjie, Li, Jie, Li, Fei, Luo, Danfeng, Ma, Xiangyi, Ma, Ding, Tan, Songwei, Wei, Rui, Xi, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214535/
https://www.ncbi.nlm.nih.gov/pubmed/34163161
http://dx.doi.org/10.2147/IJN.S298252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214535/
https://www.ncbi.nlm.nih.gov/pubmed/34163161
http://dx.doi.org/10.2147/IJN.S298252

Ejemplares similares